The U.S. Drug Enforcement Administration (DEA) has issued an emergency order placing the chemical compound SR-17018 into "Schedule I" of controlled substances, a category reserved for substances with a high potential for abuse and no recognized medical use, such as heroin. This decision sets a definitive barrier to researchers' efforts to develop an innovative medical treatment that could change the course of addressing the opioid addiction crisis.
Research led by Dr. Laura Bohn of the University of South Florida Health has shown that SR-17018 possesses unique chemical properties; it can alleviate pain without causing "respiratory depression," which is the primary cause of deaths resulting from opioid overdoses. Laboratory experiments also revealed that the compound helps reset tolerance levels in morphine-addicted subjects without causing painful withdrawal symptoms, making it a strong candidate as a medical tool to reduce opioid dependence.
Why does this decision spark scientific controversy?
The fundamental problem is that classifying the substance as "Schedule I" directly hinders the ability of scientists to conduct necessary clinical trials. Dr. Bohn explains that this ban prevents the shipping, manufacturing, or even the conducting of additional safety studies on the substance, which could lead to the freezing of decades of scientific research in the field of developing a new generation of addiction treatments.
On the other hand, users of the compound on platforms such as Reddit and Discord have described the substance as a "lifeline," as it helped some overcome addiction to stronger compounds like morphine and fentanyl without suffering from the usual physical symptoms such as anxiety, sweating, or tremors. However, attorney Robert Rush, who represents the researchers, argues that the administration's decision was "arbitrary" and ignored scientific evidence suggesting that the risks of this compound are significantly lower than other synthetic opioids.
The position of the Drug Enforcement Administration
Conversely, the Drug Enforcement Administration (DEA) justified its decision by citing the detection of samples of the compound in forensic laboratories, considering that it could be circulated and trafficked similarly to synthetic opioids. The agency also warned that the compound's ability to "reset tolerance" could make users more susceptible to the risk of overdose if they return to using traditional opioids.
This emergency ban will remain in effect for two years, with the possibility of extension, leaving the future of medical research related to this compound in a state of uncertainty, amid warnings that tightening the noose on promising substances could exacerbate the overdose crisis rather than solve it.